Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own3.20% Shs Outstand42.80M Perf Week-6.11%
Market Cap1.09B Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float42.28M Perf Month21.40%
Income-57.00M PEG- EPS next Q-0.27 Inst Own65.20% Short Float3.43% Perf Quarter580.13%
Sales6.00M P/S182.46 EPS this Y-10.10% Inst Trans13.93% Short Ratio0.46 Perf Half Y784.17%
Book/sh0.95 P/B22.34 EPS next Y16.40% ROA-64.10% Target Price25.00 Perf Year1625.20%
Cash/sh1.04 P/C20.50 EPS next 5Y- ROE-103.50% 52W Range0.70 - 25.48 Perf YTD227.98%
Dividend- P/FCF- EPS past 5Y-57.10% ROI-158.70% 52W High-12.56% Beta0.66
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin18.70% 52W Low3082.86% ATR2.49
Employees77 Current Ratio4.50 Sales Q/Q40.00% Oper. Margin- RSI (14)61.54 Volatility12.18% 10.12%
OptionableYes Debt/Eq0.27 EPS Q/Q55.50% Profit Margin- Rel Volume0.17 Prev Close21.22
ShortableYes LT Debt/Eq0.26 Earnings- Payout- Avg Volume3.16M Price22.28
Recom1.20 SMA202.07% SMA5058.14% SMA200309.11% Volume542,390 Change5.00%
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Feb-25-21 07:00AM  
Feb-22-21 07:00AM  
Feb-10-21 07:00AM  
Jan-25-21 02:40PM  
Jan-20-21 01:25PM  
12:13PM  
10:30AM  
08:45AM  
07:32AM  
04:19AM  
Jan-19-21 04:34PM  
04:01PM  
12:10PM  
07:00AM  
Dec-28-20 11:17PM  
Dec-23-20 09:11AM  
Dec-15-20 11:26PM  
07:00AM  
Nov-16-20 04:01PM  
Nov-14-20 07:08AM  
Nov-06-20 12:00PM  
Nov-04-20 08:25AM  
07:00AM  
Oct-29-20 12:35PM  
Oct-21-20 10:46AM  
Oct-20-20 07:00AM  
Oct-14-20 10:36PM  
Oct-01-20 12:00PM  
Sep-30-20 06:40AM  
Sep-01-20 04:01PM  
Aug-13-20 12:00PM  
Aug-07-20 08:45AM  
07:00AM  
Aug-06-20 12:30PM  
Jul-08-20 08:43AM  
Jul-07-20 04:01PM  
Jun-26-20 02:30PM  
Jun-18-20 10:12AM  
Jun-17-20 10:37AM  
07:01AM  
Jun-03-20 07:00AM  
May-26-20 04:01PM  
May-12-20 10:47AM  
May-08-20 12:00PM  
May-07-20 04:01PM  
May-06-20 12:30PM  
Apr-09-20 06:13AM  
Apr-06-20 12:00PM  
Apr-01-20 11:07AM  
Mar-31-20 04:01PM  
Mar-17-20 02:46AM  
Feb-25-20 04:01PM  
Feb-24-20 07:31AM  
Feb-19-20 05:00PM  
Feb-10-20 07:00AM  
Jan-13-20 05:03PM  
Jan-10-20 07:13AM  
05:40AM  
Jan-09-20 04:27PM  
Jan-08-20 08:00AM  
Dec-24-19 12:00PM  
Dec-12-19 10:33AM  
Nov-27-19 03:23PM  
Nov-21-19 11:39AM  
Nov-18-19 05:34PM  
Nov-17-19 07:14AM  
Nov-12-19 04:01PM  
Nov-07-19 04:01PM  
Oct-31-19 04:01PM  
Oct-29-19 10:33AM  
Oct-25-19 07:12AM  
Oct-24-19 04:01PM  
Oct-17-19 09:46AM  
Oct-14-19 10:28AM  
Oct-11-19 11:46AM  
Oct-10-19 04:02PM  
Oct-09-19 07:58AM  
Oct-08-19 05:01PM  
01:42PM  
Oct-07-19 07:25AM  
Oct-06-19 10:00AM  
Oct-03-19 07:28AM  
Sep-30-19 12:15PM  
10:44AM  
Sep-28-19 06:30PM  
10:00AM  
Sep-27-19 08:15PM  
03:00PM  
12:21PM  
11:00AM  
10:36AM  
Sep-26-19 04:45PM  
04:45PM  
11:17AM  
08:19AM  
Sep-25-19 08:48PM  
03:38PM  
03:15PM  
11:00AM  
10:35AM  
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehra AnandDirectorFeb 02Option Exercise18.3414,632268,29830,841Feb 03 05:33 PM